Synlogic Reports First Quarter 2022 Financial Results and Provides Business Update
May 12, 2022 07:00 ET
|
Synlogic, Inc.
- Clinical readouts anticipated for phenylketonuria (PKU), homocystinuria (HCU) and enteric hyperoxaluria programs in H2 2022 – - PKU program progressing with Phase 3 readiness activities underway – ...
Synlogic Announces First Quarter 2022 Conference Call and Webcast
May 05, 2022 07:00 ET
|
Synlogic, Inc.
CAMBRIDGE, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its...
Synlogic Announces Data Presentations at the 2022 Genetic Metabolic Dieticians International (GMDI) Conference and Garrod Symposium
April 28, 2022 07:00 ET
|
Synlogic, Inc.
CAMBRIDGE, Mass., April 28, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its...
Synlogic Announces Data Presentations from Five Programs at the 2022 Synthetic Biology: Engineering, Evolution & Design (SEED) Conference
April 26, 2022 07:00 ET
|
Synlogic, Inc.
CAMBRIDGE, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its...
Synlogic to Present Data on Phenylketonuria and Homocystinuria Programs at the Society for Inherited Metabolic Disorders 43rd Annual Meeting
April 01, 2022 07:00 ET
|
Synlogic, Inc.
CAMBRIDGE, Mass., April 01, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its...
Synlogic Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
March 17, 2022 07:00 ET
|
Synlogic, Inc.
- Phenylketonuria (PKU) program on track for Phase 3 trial initiation in H2 2022 – - Clinical readouts anticipated for PKU program in H1 2022 and in homocystinuria and enteric hyperoxaluria in H2...
Synlogic Announces Fourth Quarter and Full Year 2021 Conference Call and Webcast
March 10, 2022 07:00 ET
|
Synlogic, Inc.
CAMBRIDGE, Mass., March 10, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its...
Synlogic Announces Appointment of Michael Jensen as Chief Financial Officer
March 03, 2022 07:00 ET
|
Synlogic, Inc.
CAMBRIDGE, Mass., March 03, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its...
Synlogic To Present at Upcoming Investor and Industry Conferences
February 24, 2022 07:00 ET
|
Synlogic, Inc.
CAMBRIDGE, Mass., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its...
Synlogic To Present at Upcoming Investor and Industry Conferences
February 08, 2022 07:00 ET
|
Synlogic, Inc.
CAMBRIDGE, Mass., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its...